SCHEMBL7248157

SCHEMBL7248157

CCC(=O)c1cc[nH]c(=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
BRD4 O60885 1/20 0.41
BAZ2B Q9UIF8 1/20 0.41
BAZ2A Q9UIF9 1/20 0.41
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 3/20 0.39
SIGMAR1 Q99720 1/20 0.39
POLB P06746 1/20 0.39
SMYD3 Q9H7B4 1/20 0.39
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
HTT P42858 1/20 0.38
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
NOTUM Q6P988 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11706244 0.78 SLC2A1 (0.46) MAPTKMT2ASMYD3MEN1CA12
SCHEMBL2969266 0.77 CA12 (0.53) MAPTSMN1; SMN2L3MBTL1KMT2APOLB
SCHEMBL13373455 0.77 CDK8 (0.49) BRD4MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL1255885 0.75 MEN1 (0.56) MAPTL3MBTL1KMT2APOLBMEN1
SCHEMBL8334023 0.74 L3MBTL1 (0.54) MAPTSMN1; SMN2L3MBTL1KMT2APOLB
SCHEMBL6163681 0.74 MEN1 (0.44) BRD4MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL2291968 0.74 KMT2A (0.41) L3MBTL1KMT2ASMYD3MEN1ALDH1A1
SCHEMBL205408 0.73 CA1 (0.48) ATMMAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL13729839 0.73 HDAC8 (0.47) SMN1; SMN2SMYD3HPGDHTTCA12
SCHEMBL31701218 0.73 MAPT (0.46) BRD4BAZ2BBAZ2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6632946-B2 Biological activity inhibiting topoisomerase I and/or topoisomerase II; antitumor agents, viricides SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2003-10-14 US disclosed
US-6436951-B1 3-HYDROXY-3-(4-OXO-4,6-DIHYDROINDOLIZINO (1,2-B) QUINOLINE-2-YL) PENTANOIC ACID, INHIBITING TOPOISOMERASE I AND/OR II; ANTITUMOR, PARASITICIDE; REACTING A PYRIDINONE WITH A QUINOLINE, CYCLIZATION, EPOXIDATION SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-08-20 US disclosed
EP-1042323-B1 NOVEL CAMPTOTHECIN TETRACYCLIC ANALOGUES, PREPARATION, METHODS, APPLICATIONS AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOD CONSEILS RECH APPLIC (FR) 2002-04-10 EP disclosed
US-20010000521-A1 New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2001-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000521-A1 New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them TOP2A, TOP1, TOP2B ATM 2278/4885BRD4 3366/4885BAZ2B 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.